MCID: PSY004
MIFTS: 67

Psychotic Disorder malady

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Psychotic Disorder

Aliases & Descriptions for Psychotic Disorder:

Name: Psychotic Disorder 12 14
Psychotic Disorders 41 69
Mental or Behavioural Disorder 12
Mental Disorders 69
Psychotic 52

Classifications:

ICD10: 33


Summaries for Psychotic Disorder

MedlinePlus : 41 psychotic disorders are severe mental disorders that cause abnormal thinking and perceptions. people with psychoses lose touch with reality. two of the main symptoms are delusions and hallucinations. delusions are false beliefs, such as thinking that someone is plotting against you or that the tv is sending you secret messages. hallucinations are false perceptions, such as hearing, seeing, or feeling something that is not there. schizophrenia is one type of psychotic disorder. people with bipolar disorder may also have psychotic symptoms. other problems that can cause psychosis include alcohol and some drugs, brain tumors, brain infections, and stroke. treatment depends on the cause of the psychosis. it might involve drugs to control symptoms and talk therapy. hospitalization is an option for serious cases where a person might be dangerous to himself or others.

MalaCards based summary : Psychotic Disorder, also known as psychotic disorders, is related to schizophrenia and autism spectrum disorder, and has symptoms including alexithymia, decreased libido and increased libido. An important gene associated with Psychotic Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Beta-Adrenergic Signaling and Circadian entrainment. The drugs Aripiprazole and Asenapine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and bone, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A cognitive disorder that involves abnormal thinking and perceptions resulting in a disconnection with reality.

Related Diseases for Psychotic Disorder

Diseases related to Psychotic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
id Related Disease Score Top Affiliating Genes
1 schizophrenia 31.1 AKT1 BDNF COMT DAOA DISC1 DRD2
2 autism spectrum disorder 29.8 BDNF COMT DRD4 SLC6A4
3 hypoglycemia 29.7 BDNF DRD2 DRD3 SLC6A4
4 personality disorder 29.2 BDNF COMT DISC1 DRD2 DRD3 DRD4
5 schizophreniform disorder 11.7
6 delusional disorder 11.0
7 drug psychosis 10.9
8 schizophrenia 17 10.7
9 schizophrenia susceptibility 18 10.7
10 schizophrenia 4 10.7
11 schizophrenia 15 10.7
12 mental retardation, x-linked, syndromic 13 10.7
13 nephronophthisis 13 10.4 COMT HTR2A SLC6A4
14 splenic abscess 10.4 DRD2 HTR2A SLC6A4
15 ornithosis 10.4 DRD2 PRL SLC6A4
16 euthyroid sick syndrome 10.4 DRD2 HTR2A SLC6A4
17 dry eye syndrome 10.4 HTR2A HTR2C SLC6A4
18 rhinoscleroma 10.3 COMT DRD2 NRG1 PRL
19 intrahepatic gall duct cancer 10.3 BDNF COMT HTR2A SLC6A4
20 chronic eosinophilic pneumonia 10.3 BDNF COMT PRL SLC6A4
21 colorectal adenocarcinoma 10.3 COMT DRD2 DRD4 SLC6A4
22 apperceptive agnosia 10.3 COMT DRD2 SLC6A4
23 postencephalitic parkinson disease 10.3 BDNF DRD2 HTR2A SLC6A4
24 chondrodysplasia lethal recessive 10.3 COMT DAOA NRG1 PRL
25 strongyloidiasis 10.3 COMT DRD2 MAOB SLC6A4
26 chagas disease 10.3 BDNF COMT HTR2A SLC6A4
27 carotid stenosis 10.3 COMT DRD2 DRD4 SLC6A4
28 waardenburg's syndrome 10.3 DRD2 HTR2A HTR2C SLC6A4
29 hypoglycemic coma 10.3 BDNF HTR2A SLC6A4
30 urea cycle disorder 10.3 BDNF COMT DRD2 S100B
31 breast reconstruction 10.3 BDNF COMT DRD2 S100B
32 pulmonary neuroendocrine tumor 10.3 DRD2 PRL S100B
33 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 10.3 BDNF COMT HTR2A PRL SLC6A4
34 rectosigmoid junction neoplasm 10.3 DRD2 DRD4 SLC18A2
35 hereditary multiple exostoses 10.3 BDNF COMT DRD2 HTR2A SLC6A4
36 nephrogenic adenoma of the urethra 10.3 DRD2 MAOB PRL SLC18A2 SLC6A4
37 multiple personality disorder 10.3 BDNF COMT HTR2A HTR2C SLC6A4
38 keratosis 10.3 BDNF COMT HTR2A HTR2C SLC6A4
39 interstitial emphysema 10.3 DRD2 HTR2C SLC6A4
40 ovarian mucinous adenocarcinoma 10.3 AKT1 BDNF MAOB SLC18A2
41 cholesteatoma 10.3 BDNF COMT DRD2 HTR2C SLC6A4
42 teratoma with malignant transformation 10.3 BDNF DRD2 DRD3 HTR2A
43 mastitis 10.3 DRD4 HLA-A PRL
44 hepatitis b reinfection following liver transplantation 10.3 HTR2A MAOB SLC6A4
45 intracranial aneurysm 10.3 DRD2 DRD3 DRD4
46 c8 deficiency, type ii 10.3 COMT DRD2 DRD3 DRD4
47 transmitted_by 10.3 DRD2 DRD3 PRL SLC6A4
48 epithelioid type angiomyolipoma 10.3 BDNF HTR2A MAOB SLC18A2 SLC6A4
49 sphenoorbital meningioma 10.3 DRD2 DRD3 DRD4 HLA-A
50 lichen disease 10.3 COMT HTR2A SLC6A4

Graphical network of the top 20 diseases related to Psychotic Disorder:



Diseases related to Psychotic Disorder

Symptoms & Phenotypes for Psychotic Disorder

UMLS symptoms related to Psychotic Disorder:


alexithymia, decreased libido, increased libido, lethargy, nervousness, numbness, agitation, psychiatric symptom, hallucinations, auditory, hallucinations, visual, reduced consciousness/confusion, numbness localized, feeling detached, feeling strange, feeling weightless, floating feeling, dejection emotional, depressed reaction, hallucinations, sensory, restless sleep, difficulty sleeping, excitability, depression aggravated, agitation mental, numb mouth, forgetful, feeling jittery, opiate withdrawal symptoms, clouded consciousness, trembling inside, sluggishness, symptoms, fatigue, sleep disturbances, photophobia, mental and behavioral signs and symptoms, personality changes, catatonic reaction, restlessness, pseudobulbar behavioral symptoms

MGI Mouse Phenotypes related to Psychotic Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.3 DRD2 DRD3 DRD4 DTNBP1 GABRB3 HTR2A
2 homeostasis/metabolism MP:0005376 10.1 AKT1 BDNF COMT DISC1 DRD2 DRD3
3 digestive/alimentary MP:0005381 9.87 BDNF DRD2 DRD3 GABRB3 HTR2A RELN
4 integument MP:0010771 9.81 AKT1 BDNF DRD2 DTNBP1 HTR2C PRL
5 muscle MP:0005369 9.56 AKT1 RELN SLC18A2 SLC6A4 DRD2 DTNBP1
6 nervous system MP:0003631 9.5 AKT1 BDNF COMT DISC1 DRD2 DRD3

Drugs & Therapeutics for Psychotic Disorder

Drugs for Psychotic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 811)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
2
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 85650-56-2, 65576-45-6 3001386
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Haloperidol Approved Phase 4,Phase 3,Phase 2,Phase 1 52-86-8 3559
5
Lorazepam Approved Phase 4,Phase 3,Phase 2,Phase 1 846-49-1 3958
6
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Phase 1 146939-27-7 60854
7
Sulpiride Approved Phase 4,Phase 3,Phase 2,Phase 1 15676-16-1 5355
8
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59729-33-8 2771
9
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3 298-46-4 2554
10
Coal tar Approved Phase 4,Phase 2 8007-45-2
11
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
12
Oxcarbazepine Approved Phase 4,Phase 2,Phase 3 28721-07-5 34312
13
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99-66-1 3121
14
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
15
Zolpidem Approved Phase 4,Phase 3,Phase 2 82626-48-0 5732
16 Zotepine Approved Phase 4 26615-21-4
17
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
18
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
19
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
20
Chlorpromazine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-53-3 2726
21
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 249296-44-4 5310966
22
Guanfacine Approved, Investigational Phase 4,Phase 2,Phase 1 29110-47-2 3519
23
Armodafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 112111-43-0
24
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 68693-11-8 4236
25
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
26
Clozapine Approved Phase 4,Phase 3,Phase 2,Phase 1 5786-21-0 2818
27
Etomidate Approved Phase 4 33125-97-2 36339 667484
28
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
29 Moxonidine Approved Phase 4 75438-57-2 4810
30
Reboxetine Approved, Investigational Phase 4,Phase 1 98769-81-4, 71620-89-8 123628 65856
31
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 10118-90-8 5281021
32
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 51-41-2 439260
33
Carbidopa Approved Phase 4,Phase 2 28860-95-9 34359 38101
34
Levodopa Approved Phase 4,Phase 2 59-92-7 6047
35
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
36
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
37
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
38
Nicotine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 54-11-5 942 89594
39
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 28981-97-7 2118
40
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
41
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
42
Dronabinol Approved, Illicit Phase 4,Phase 1 1972-08-3 16078 2978
43
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54910-89-3 3386
44
Guaifenesin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 93-14-1 3516
45
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
46
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
47
Amphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 300-62-9 5826 3007
48
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97240-79-4 5284627
49
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
50
Sevoflurane Approved, Vet_approved Phase 4,Phase 1,Phase 2 28523-86-6 5206

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4
2 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4
3 Investigator Initiated Study - Asenapine Early Psychosis Unknown status NCT01968161 Phase 4
4 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Unknown status NCT01155544 Phase 4
5 Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) Unknown status NCT01822418 Phase 4
6 Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia Unknown status NCT02210962 Phase 4
7 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Unknown status NCT01153490 Phase 4
8 Ziprasidone vs Standard Therapy for Agitated Patients in the ED Unknown status NCT00786318 Phase 4
9 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4
10 Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4
11 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4
12 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4
13 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4
14 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4
15 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4
16 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4
17 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4
18 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4
19 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4
20 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4
21 Varenicline Adjunctive Treatment in Schizophrenia Unknown status NCT00492349 Phase 4
22 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4
23 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4
24 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4
25 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
26 Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia Unknown status NCT02049021 Phase 4
27 Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia Unknown status NCT02040883 Phase 4
28 Alleviating the Metabolic Side Effects of Antipsychotic Medications Unknown status NCT01567124 Phase 4
29 Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia Unknown status NCT01300364 Phase 4
30 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4
31 Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype Unknown status NCT01078870 Phase 4
32 Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4
33 Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning Unknown status NCT00937261 Phase 4
34 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4
35 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4
36 The New Strategy for Pharmacological Treatment in People With Schizophrenia Unknown status NCT00352339 Phase 4
37 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4
38 PREvent First Episode Relapse (PREFER) Unknown status NCT00220714 Phase 4
39 Optimization of Acute Treatment in First Episode Schizophrenia Unknown status NCT00157378 Phase 4
40 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Unknown status NCT01683253 Phase 4
41 Testosterone Patch's Effects on the Cardiovascular System and Libido Unknown status NCT01208038 Phase 4
42 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
43 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4
44 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
45 A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia Unknown status NCT01490567 Phase 4
46 Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Unknown status NCT00802919 Phase 4
47 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4
48 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4
49 Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release Unknown status NCT00492414 Phase 4
50 Add on Study on Δ9-THC Treatment for Posttraumatic Stress Disorders (PTSD) Unknown status NCT00965809 Phase 4

Search NIH Clinical Center for Psychotic Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Psychotic Disorder

Anatomical Context for Psychotic Disorder

MalaCards organs/tissues related to Psychotic Disorder:

39
Brain, Heart, Bone, Pituitary, Testes, Small Intestine, Temporal Lobe

Publications for Psychotic Disorder

Articles related to Psychotic Disorder:

(show top 50) (show all 356)
id Title Authors Year
1
Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter-observational study. ( 28517032 )
2017
2
Cognitive changes in alcohol-induced psychotic disorder. ( 28446210 )
2017
3
Exploring the use of Routine Outcome Monitoring in the treatment of patients with a psychotic disorder. ( 28314165 )
2017
4
Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study. ( 28464965 )
2017
5
Evidence that polygenic risk for psychotic disorder is expressed in the domain of neurodevelopment, emotion regulation and attribution of salience. ( 28436345 )
2017
6
Serum S100B: A proxy marker for grey and white matter status in the absence and presence of (increased risk of) psychotic disorder? ( 28358925 )
2017
7
Evidence That the Impact of Childhood Trauma on IQ Is Substantial in Controls, Moderate in Siblings, and Absent in Patients With Psychotic Disorder. ( 28177077 )
2017
8
GRIN3B missense mutation as an inherited risk factor for schizophrenia: whole-exome sequencing in a family with a familiar history of psychotic disorders. ( 28132660 )
2017
9
Emergence of new-onset psychotic disorder following recovery from LGI1 antibody-associated limbic encephalitis. ( 28363946 )
2017
10
Outcome of acute and transient psychotic disorder in an index episode: A study from a tertiary care centre in North India. ( 28262127 )
2017
11
Abnormal frontoparietal synaptic gain mediating the P300 in patients with psychotic disorder and their unaffected relatives. ( 28345275 )
2017
12
Clinical consequences of extensive routine laboratory investigations in patients with a recent onset psychotic disorder. ( 28162811 )
2017
13
No Evidence of Association between Childhood Urban Environment and Cortical Thinning in Psychotic Disorder. ( 28045900 )
2017
14
Does the Social Functioning Scale reflect real-life social functioning? An experience sampling study in patients with a non-affective psychotic disorder and healthy control individuals. ( 28534464 )
2017
15
Antipsychotic treatment and the Rorschach Perceptual Thinking Index (PTI) in psychotic disorder patients: Effects of treatment. ( 28236781 )
2017
16
A case report of brief psychotic disorder with catalepsy associated with sequential life-threatening events in a patient with advanced cancer. ( 28413438 )
2017
17
Outcome of first-episode acute and transient psychotic disorder in Hong Kong Chinese: a 20-year retrospective follow-up study. ( 27834101 )
2017
18
Factors Associated with Timely Physician Follow-up after a First Diagnosis of Psychotic Disorder. ( 27738261 )
2016
19
Comparing the experience of voices in borderline personality disorder with the experience of voices in a psychotic disorder: A systematic review. ( 26912339 )
2016
20
A Network Approach to Environmental Impact in Psychotic Disorder: Brief Theoretical Framework. ( 27179124 )
2016
21
Social functioning in patients with a psychotic disorder and first rank symptoms. ( 26892072 )
2016
22
Association study of GABA system genes polymorphisms with amphetamine-induced psychotic disorder in a Han Chinese population. ( 27080428 )
2016
23
Clinical Course of Methamphetamine-Induced Psychotic Disorder in a 3-Month Follow-Up. ( 27907276 )
2016
24
Porencephalic cyst and late onset brief psychotic disorder. ( 27053544 )
2016
25
A linguistic comparison between auditory verbal hallucinations in patients with a psychotic disorder and in nonpsychotic individuals: Not just what the voices say, but how they say it. ( 27501385 )
2016
26
Urinary dopamine in psychotic disorders is similar to that of pheochromocytoma and paraganglioma. ( 27653463 )
2016
27
Short-term outcome of substance-induced psychotic disorder in a large UK first episode psychosis cohort. ( 27479903 )
2016
28
Do routine outcome monitoring results translate to clinical practice? A cross-sectional study in patients with a psychotic disorder. ( 27091333 )
2016
29
Differential Time Course of Microstructural White Matter in Patients With Psychotic Disorder and Individuals at Risk: A 3-Year Follow-up Study. ( 27190279 )
2016
30
Evidence of an excessive gender gap in the risk of psychotic disorder among North African immigrants in Europe: a systematic review and meta-analysis. ( 27372300 )
2016
31
Safety of Transcranial Direct Current Stimulation in Alcohol-Induced Psychotic Disorder with Comorbid Psoriasis. ( 27011409 )
2016
32
Effect of virtual reality exposure therapy on social participation in people with a psychotic disorder (VRETp): study protocol for a randomized controlled trial. ( 26762123 )
2016
33
Life-threatening ketoacidosis in a pregnant woman with psychotic disorder. ( 27512491 )
2016
34
Letter to the Editor: Comparison of cognitive functions, pre-morbid conditions and clinical characteristics between brief psychotic disorder and schizophrenia. ( 27181416 )
2016
35
Reduced specialized processing in psychotic disorder: a graph theoretical analysis of cerebral functional connectivity. ( 27688938 )
2016
36
Psychotic disorder associated with 22q11.2 duplication syndrome. ( 26763109 )
2016
37
Resilience in patients with psychotic disorder. ( 27110878 )
2016
38
Indomethacin-Induced Psychotic Disorder. ( 27046657 )
2016
39
Influence of DAOA and RGS4 genes on the risk for psychotic disorders and their associated executive dysfunctions: A family-based study. ( 26803614 )
2016
40
Early-Life Stress Affects Stress-Related Prefrontal Dopamine Activity in Healthy Adults, but Not in Individuals with Psychotic Disorder. ( 27007554 )
2016
41
Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. ( 27828960 )
2016
42
Cognitive Performance and Long-Term Social Functioning in Psychotic Disorder: A Three-Year Follow-Up Study. ( 27082629 )
2016
43
BEATVIC, a body-oriented resilience training with elements of kickboxing for individuals with a psychotic disorder: study protocol of a multi-center RCT. ( 27393604 )
2016
44
Self-Reported Reasons for Smoking: Predicting Abstinence and Implications for Smoking Cessation Treatments Among Those With a Psychotic Disorder. ( 27982748 )
2016
45
Interplay between Schizophrenia Polygenic Risk Score and Childhood Adversity in First-Presentation Psychotic Disorder: A Pilot Study. ( 27648571 )
2016
46
Mentalization-based treatment for psychotic disorder: protocol of a randomized controlled trial. ( 27278250 )
2016
47
Misdiagnosis of cerebral malaria initially as acute psychotic disorder and later as human rabies: a case report. ( 27514689 )
2016
48
Bullying victimisation increases the risk of emergence and persistence of specific psychotic symptoms and of psychotic disorder. ( 26718965 )
2016
49
The prevalence and correlates of self-harm in pregnant women with psychotic disorder and bipolar disorder. ( 27173485 )
2016
50
Novel gene-brain structure relationships in psychotic disorder revealed using parallel independent component analyses. ( 27789186 )
2016

Variations for Psychotic Disorder

Expression for Psychotic Disorder

Search GEO for disease gene expression data for Psychotic Disorder.

Pathways for Psychotic Disorder

Pathways related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 AKT1 BDNF DRD2 DRD3 DRD4
2
Show member pathways
12.47 AKT1 COMT DRD2 DRD3 DRD4 MAOB
3
Show member pathways
12.17 AKT1 DRD2 HTR2A HTR2C
5
Show member pathways
11.74 BDNF DRD2 MAOB SLC18A2
6 11.71 DRD3 DRD4 HTR2A
7
Show member pathways
11.63 DRD2 DRD3 DRD4 SLC18A2
8
Show member pathways
11.61 DRD2 DRD3 DRD4 HTR2A HTR2C
9 11.51 BDNF S100B SLC18A2
10 11.15 GABRB3 HTR2A HTR2C MAOB SLC18A2 SLC6A4
11 10.7 HTR2A HTR2C SLC18A2 SLC6A4
12 10.66 COMT MAOB
13
Show member pathways
10.64 COMT MAOB

GO Terms for Psychotic Disorder

Cellular components related to Psychotic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.73 BDNF DRD2 DTNBP1 GABRB3 HTR2A SLC18A2
2 dendrite GO:0030425 9.72 COMT DRD2 HTR2A NRG1 RELN
3 postsynaptic membrane GO:0045211 9.71 COMT DISC1 DTNBP1 GABRB3
4 cell body GO:0044297 9.61 COMT DISC1 NRG1
5 axon GO:0030424 9.43 COMT DISC1 DRD2 DTNBP1 HTR2A NRG1
6 integral component of plasma membrane GO:0005887 9.32 DRD2 DRD3 DRD4 GABRB3 HLA-A HTR2A
7 membrane GO:0016020 10.27 AKT1 COMT DISC1 DRD2 DRD3 DRD4
8 plasma membrane GO:0005886 10.03 AKT1 COMT DISC1 DRD2 DRD3 DRD4

Biological processes related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
id Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.9 DRD2 DRD3 MAOB PRL
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.87 HTR2A NRG1 RELN
3 response to toxic substance GO:0009636 9.85 DRD2 MAOB SLC18A2 SLC6A4
4 memory GO:0007613 9.84 HTR2A S100B SLC6A4
5 cellular calcium ion homeostasis GO:0006874 9.84 DRD3 DRD4 HTR2A HTR2C
6 synapse assembly GO:0007416 9.83 BDNF DRD2 NRG1
7 learning GO:0007612 9.82 COMT DRD3 RELN
8 social behavior GO:0035176 9.8 DRD3 DRD4 SLC6A4
9 positive regulation of fat cell differentiation GO:0045600 9.8 AKT1 HTR2A HTR2C
10 locomotory behavior GO:0007626 9.8 DRD2 DRD3 HTR2C NRG1 SLC18A2
11 release of sequestered calcium ion into cytosol GO:0051209 9.78 DRD2 HTR2A HTR2C
12 negative regulation of adenylate cyclase activity GO:0007194 9.73 DRD2 DRD3 DRD4
13 glial cell differentiation GO:0010001 9.71 NRG1 RELN
14 startle response GO:0001964 9.71 DRD2 NRG1
15 positive regulation of kinase activity GO:0033674 9.71 DRD4 HTR2A
16 TOR signaling GO:0031929 9.7 AKT1 DISC1
17 behavioral response to ethanol GO:0048149 9.7 DRD2 DRD4
18 positive regulation of long-term synaptic potentiation GO:1900273 9.7 DRD2 RELN
19 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.7 DRD2 HTR2A
20 prepulse inhibition GO:0060134 9.69 DRD2 DRD3
21 positive regulation of renal sodium excretion GO:0035815 9.69 DRD2 DRD3
22 negative regulation of voltage-gated calcium channel activity GO:1901386 9.68 DRD2 DRD4
23 G-protein coupled receptor internalization GO:0002031 9.68 DRD2 DRD3
24 behavior GO:0007610 9.68 HTR2A HTR2C
25 neurotransmitter catabolic process GO:0042135 9.67 COMT MAOB
26 regulation of behavior GO:0050795 9.67 HTR2A RELN
27 monoamine transport GO:0015844 9.67 SLC18A2 SLC6A4
28 arachidonic acid secretion GO:0050482 9.67 DRD2 DRD3 DRD4
29 response to amphetamine GO:0001975 9.67 DRD2 DRD3 DRD4 SLC18A2
30 dopamine catabolic process GO:0042420 9.66 COMT MAOB
31 serotonin receptor signaling pathway GO:0007210 9.65 HTR2A HTR2C
32 dopamine receptor signaling pathway GO:0007212 9.65 DRD2 DRD3 DRD4
33 inhibitory postsynaptic potential GO:0060080 9.64 DRD4 GABRB3
34 chemical synaptic transmission, postsynaptic GO:0099565 9.64 AKT1 DRD2
35 regulation of cAMP metabolic process GO:0030814 9.63 DRD2 DRD3
36 negative regulation of protein secretion GO:0050709 9.63 DRD2 DRD3 DRD4
37 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.62 DRD2 DRD3
38 regulation of dopamine secretion GO:0014059 9.62 DRD2 DRD3 DTNBP1 HTR2A
39 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.61 HTR2A HTR2C
40 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.61 DRD2 DRD3 DRD4
41 negative regulation of dopamine receptor signaling pathway GO:0060160 9.59 DRD2 DRD3
42 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.58 DRD2 DRD4
43 acid secretion GO:0046717 9.58 DRD2 DRD3
44 serotonin transport GO:0006837 9.57 SLC18A2 SLC6A4
45 behavioral response to cocaine GO:0048148 9.56 DRD2 DRD3 DRD4 HTR2A
46 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.52 HTR2A HTR2C
47 regulation of locomotion involved in locomotory behavior GO:0090325 9.51 DRD2 DRD3
48 response to histamine GO:0034776 9.33 DRD2 DRD3 DRD4
49 dopamine metabolic process